Researchers have discovered a new treatment that could improve autism-related behaviors by restoring brain signaling in mouse models. This approach targets a glycine transporter called SLC6A20, which, when blocked, enhances the function of NMDA receptors. These receptors are crucial for communication between brain cells and play a significant role in learning and memory. The study found that this treatment not only improved social interactions and reduced repetitive behaviors in mice but also showed lasting effects, suggesting that brain function may be more adaptable in adulthood than previously believed.

For adults interested in healthy aging and brain function, this research highlights a potential pathway for addressing cognitive and behavioral challenges linked to autism spectrum disorder (ASD). The treatment was tested on mice with mutations related to autism, and the results indicate significant improvements in social communication and behavior. The effects were noted to last for at least eight weeks, which is promising for those looking for long-term solutions to cognitive issues.

While the findings are encouraging, they are still in the early stages. The research involved animal models and human brain organoids, which means more studies are needed to determine how this treatment could translate to humans. The approach shows promise for not just autism but also other conditions associated with NMDA receptor dysfunction, such as schizophrenia and intellectual disabilities.

As this research progresses, it could pave the way for new therapeutic strategies that might help improve cognitive function and social behaviors in people with neurodevelopmental disorders. However, it’s important to note that these findings are preliminary, and further studies are necessary to confirm their effectiveness in humans.

Source: Institute for Basic Science